Disclosure SP has received education grants, provided consultation, attended advisory boards and/or provided lectures for the following organizations, from whom he has received honoraria (all fees to institution): Consultation/Advisory role: AbbVie, AiCME, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BerGenBio, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Illumina, Imedex, IQVIA, Incyte, Ipsen, iTeos, Janssen, Medscape, Medtoday, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, Novocure, OncologyEducation, Pharma Mar, Promontory Therapeutics, PER, Peerview, Pfizer, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody. Talk in a company’s organized public event: AiCME, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Foundation Medicine, GSK, Illumina, Imedex, Ipsen, Medscape, Merck Sharp and Dohme, Mirati, Novartis, PER, Peerview, Pfizer, Roche/Genentech, RTP, Sanofi, Takeda. Receipt of grants/research supports: Principal investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, Arcus, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, iTeos, Merck Sharp and Dohme, Mirati, Pharma Mar, Promontory Therapeutics, Roche/Genentech, Seattle Genetics. RG reports being an invited speaker from Apogen, Lilly, Mylan, Novartis, Roche, Pfizer, Medicines for Europe, Mabxience and the European Access Academy (all with no fee received); received personal fees from AstraZeneca; she reports an advisory role for Cancer Drug Development Forum (for a meeting in 2023), from UICC ATOM Medicines (January 2023); she reports being a full member of the Cancer Drug Development Forum (CDDF); she is a member of the EUnetHTA Stakeholder group, co-chair and member of the European Medicines Agency (EMA) Healthcare Professional Working Party (HCPWP); she reports having a consultative role for the AIFA (Italian Medicines Agency) working group on hemato-oncology drugs, core member of the EMA Scientific Advisory Group-Oncology (Apr 2012-June 2021), steering committee member of the WHO-DECIDE Health Decision Hub (until December 2022); she is a member of the EMA Cancer Medicines Forum; she serves as an expert for the evaluation of proposals submitted to Horizon Europe Health Cluster—for the Health and Digital Executive Agency (HaDEA). JS—Research Funding: Roche Pharma, AstraZeneca, Bayer, Clovis, GlaxoSmith, Lilly, Tesaro. Honorary: Tesaro, GlaxoSmith, PharmaMar, AstraZeneca, Clovis, Bayer, Roche PharmaMar, Vifor Pharma, Hexal AG, Novartis Pharma. Consulting: Tesaro, Merck/Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma; GlaxoSmith, MSD, Eisai, Novocure, Oncoinvent. AU—Research Funding: none. Honorary: none. Consulting: Roche Pharma. All other authors have declared no conflicts of interest.